1. Cell Cycle/DNA Damage
  2. PERK


Protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK) is activated in response to a variety of endoplasmic reticulum stresses implicated in numerous disease states. PERK is implicated in tumorigenesis and cancer cell survival. GSK2606414 is an orally available, potent, and selective PERK inhibitor. GSK2606414 inhibits PERK activation in cells and inhibits the growth of a human tumor xenograft in mice. PERK activation is independent of the large increase in unfolded nascent proteins within the ER following transient global brain ischemia.

PERK Related Products (4):

Cat. No. Product Name Effect Purity
  • HY-18072
    GSK2606414 Inhibitor 99.38%
    GSK2606414 is a cell-permeable and orally available PERK inhibitor with an IC50 of 0.4 nM.
  • HY-13820
    GSK2656157 Inhibitor 99.66%
    GSK2656157 is a selective and ATP-competitive inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK) with an IC50 of 0.9 nM.
  • HY-12495
    ISRIB trans-isomer Inhibitor >98.0%
    ISRIB (trans-isomer) is a potent inhibitor of PERK with an IC50 of 5 nM.
  • HY-119240
    CCT020312 Activator 98.56%
    CCT020312 is capable of delivering potent, and eukaryotic initiation factor 2-alpha kinase 3 (EIF2AK3) selective, proliferation control and also is an activator of RNA-like endoplasmic reticulum kinase (PERK).
Isoform Specific Products

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.